• Disciplinary proceedings opened against Croatian Football Federation
  
• Fowl Ball” Could Be A Huge Hit For Young Sluggers
  
• New Chief Executive of the Meat Hygiene Service appointed
  
• Sale of British Airways Travel Clinic
  
• Lufthansa resumes flights to Beirut
  
• Partnership for Change with Air Navigation Service Providers, Cost Efficiency, Environment
  
• Head-to-head study comparing Lexiva® to Kaletra presented at IAC 2006 and published in The Lancet
  
• Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant TM
  
• Medicines, money and motivated health workers are key...
  
• Skindividual preserve skin’s youthful beauty
  
• A weekend in Paris
  
• Fifth Annual EA Sports Madden Challenge Starts September 1st to...
  
• Akamai and Instant Media Team to Deliver Seamless High-Definition Internet Video Experience
  
• Teva Announces Launch of Generic Zoloft®
  
• Zoller Wine Styling Offers Custom Made Premium Winemaking
  

Teva Provides Update on Generic Pravachol Exclusivity

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that United States Court of Appeals for the District of Columbia has vacated the FDA s determination...

that Teva s exclusivity on pravastatin 10, 20, and 40 mg had been triggered and remanded the matter back to the FDA for further decision-making. The FDA has advised the Court that in the event of a remand the FDA would determine that Teva maintains exclusivity on these products and Teva expects final approval with exclusivity in April 2006 when the product patent expires. The Court has also vacated the lower court s prior decision that Teva maintains its exclusivity, so that FDA can provide its reasoning for rejecting the challenge to Teva s exclusivity.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90% of Teva s sales are in North America and Europe.

Teva Pharmaceutical Industries Ltd.

• Teva Announces Launch of Generic Zoloft®
  
• Teva Provides Generic Biaxin® Xl Update
  
• Teva Announces Tentative Approval for Generic Cozaar® Tablets
  
• Teva Provides Update on Generic Pravachol Exclusivity
  
• Teva Comments on Pfizer Press Release Regarding Azithromycin
  
• Teva Announces Approval of Cefprozil Tablets and Cefprozil for Oral Suspension Usp
  
• Teva and Ivax Receive European Commission Approval for Acquisition
  
• Teva and Barr Announce Launch of Generic Allegra® Tablets by Teva Under Agreement With Barr
  
• Court Grants Teva Summary Judgment of Non-Infringement on Gabapentin
  
• Teva Announces Tentative Approval of Granisetron Hydrochloride Injection